• Please Remember: Members are only permitted to share their own experiences. Members are not qualified to give medical advice. Additionally, everyone manages their health differently. Please be respectful of other people's opinions about their own diabetes management.
  • We seem to be having technical difficulties with new user accounts. If you are trying to register please check your Spam or Junk folder for your confirmation email. If you still haven't received a confirmation email, please reach out to our support inbox: support.forum@diabetes.org.uk

One-shot lifetime cholesterol lowering - getting closer

Eddy Edson

Eddy Edson

Well-Known Member
Relationship to Diabetes
In remission from Type 2
Lily is buying start-up Verve Therapeutics, whose one-shot gene editing technology is showing promise of lifetime 50%+ reductions in LDL-C in early trials.


"VERVE-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development.

(Still some risk, and anyway years to market. Plenty of time for the people in the business of spreading statin misinformation to plan ahead for this new target.)
 
Wow! Be interesting to see how this plays out as the trials continue. There has been already quite a lot of Internet Anxiety around whether or not new medicines interacted with DNA, so I’d imagine there will be a degree of uncertainty in many people. But I can see the appeal of a “this thing permanently fixes that problem” interaction.

Though like many new medical approaches, unfortunately my brain immediately jumps to thinking about one of the early scenes in a zombie apocalypse / planet of the apes movie 😱
 
everydayupsanddowns said:
Wow! Be interesting to see how this plays out as the trials continue. There has been already quite a lot of Internet Anxiety around whether or not new medicines interacted with DNA, so I’d imagine there will be a degree of uncertainty in many people. But I can see the appeal of a “this thing permanently fixes that problem” interaction.

Though like many new medical approaches, unfortunately my brain immediately jumps to thinking about one of the early scenes in a zombie apocalypse / planet of the apes movie 😱
Click to expand...
Yes, "zombie apocalypse" should be a fruitful angle for people constructing misinformation. Seems like it should be an easier task than manufacturing woo about statins being risky and/or useless from basically zero evidence.
 
I’ve just seen this post.
Mr Eggy is part of a trial for a one shot a year, I think it is, of a statin. It’s called the Orian Trial. He was approached just before Covid, for context he has a complex chronic heart condition ( six heart attacks) but for obvious reasons it stopped. It restarted three years ago. He obviously doesn’t know whether he’s taking the placebo or the real thing. He goes twice a year, they give him a jab, take bloods but never tell him the results. He’s just been last month. His last time is this December. I wonder if it’s a similar thing? I wonder if they’ll tell him the results? Interesting.
 
I reckon this would be the ORION-4 trial, looking at inclisiran for people with a history of MACE (ie major CV events).

Homepage — ORION 4

www.orion4trial.org www.orion4trial.org

Inclisiran is in the class of drugs called "PCSK9 inhibitors". Very powerful drugs & inclisiran as you say is long-lasting with a shot every six months. But not the same as this new thing, which is a once-and-done, gene editing therapy.
 
MarcR said:
what is they find out the reduction is harmful, can the change be undone?
Click to expand...
Verve in many ways replicates the natural mutations seen in a fair number of people which prevent/lower the expresion of proteins by the PCSK9 gene which interfere with LDL-C clearance. People with these mutations see LDL-C levels of 0.5 mmol/l or lower, with no ill effects & greatly reduced rates of CV disease.

(Verve differences include targeting just the liver, not the whole body effect of the mutations).

PCSK9 inhibitors like inclisitan act differently but with similar LD-C lowering effects. No adverse effects from low LDL-C levels in multiple trials.

In general, your organs manufacture whatever LDL-C they need. LDL-C in the blood is essentially just a waste product and large scale repeated tests have found no lower limit for safety.
 
Last edited:
You must log in or register to reply here.
Back
Top